#BEGIN_DRUGCARD DB00474

# AHFS_Codes:
Not Available

# ATC_Codes:
N01AF01
N05CA15

# Absorption:
The absolute bioavailability following rectal administration of methohexital is 17%.

# Biotransformation:
Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.

# Brand_Mixtures:
Not Available

# Brand_Names:
Brevital
Brevital sodium
Brietal

# CAS_Registry_Number:
151-83-7

# ChEBI_ID:
102216

# Chemical_Formula:
C14H18N2O3

# Chemical_IUPAC_Name:
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
128678

# Description:
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]

# Dosage_Forms:
Injection, powder, for solution	Intramuscular
Injection, powder, for solution	Intravenous

# Drug_Category:
Anesthetics
Anesthetics, Intravenous
Barbiturates

# Drug_Interactions:
Aminophylline	The barbiturate, methohexital, decreases the effect of aminophylline.
Betamethasone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone.
Clomifene	The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene.
Conjugated Estrogens	The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens.
Cyclosporine	The barbiturate, methohexital, increases the effect of cyclosporine.
Dexamethasone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone.
Diethylstilbestrol	The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol.
Doxycycline	The anticonvulsant, methohexital, decreases the effect of doxycycline.
Estradiol	The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol.
Ethinyl Estradiol	This product may cause a slight decrease of contraceptive effect
Felodipine	The barbiturate, methohexital, decreases the effect of felodipine.
Fludrocortisone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone.
Folic Acid	Folic acid decreases the effect of anticonvulsant, methohexital.
Gefitinib	The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib.
Griseofulvin	The barbiturate, methohexital, decreases the effect of griseofulvin.
Hydrocortisone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone.
Levonorgestrel	Phenobarbital decreases the effect of levonorgestrel
Medroxyprogesterone	The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone.
Megestrol	The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol.
Methadone	The barbiturate, methohexital, decreases the effect of methadone.
Metronidazole	The barbiturate, methohexital, decreases the effect of metronidazole.
Nifedipine	The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine.
Norethindrone	This product may cause a slight decrease of contraceptive effect
Oxtriphylline	The barbiturate, methohexital, decreases the effect of oxtriphylline.
Prednisolone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone.
Prednisone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
Quinidine	The anticonvulsant, methohexital, decreases the effect of quinidine.
Theophylline	The barbiturate, methohexital, decreases the effect of theophylline.
Triamcinolone	The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone.
Trimipramine	The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required.
Triprolidine	The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Verapamil	Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed.
Warfarin	Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Methohexital

# HET_ID:
Not Available

# Half_Life:
5.6 &plusmn; 2.7 minutes

# InChI_Identifier:
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)

# InChI_Key:
InChIKey=NZXKDOXHBHYTKP-UHFFFAOYSA-N

# Indication:
Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.

# KEGG_Compound_ID:
C07844

# KEGG_Drug_ID:
D04985

# LIMS_Drug_ID:
474

# Mechanism_Of_Action:
Methohexital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
262.3043

# Molecular_Weight_Mono:
262.131742452

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164784030

# Pharmacology:
Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

# Predicted_LogP_Hydrophobicity:
2.43

# Predicted_LogS:
-3.7

# Predicted_Water_Solubility:
5.24e-02 g/l

# Primary_Accession_No:
DB00474

# Protein_Binding:
73%

# PubChem_Compound_ID:
9034

# PubChem_Substance_ID:
46507954

# RxList_Link:
http://www.rxlist.com/cgi/generic3/methohexital.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00058

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Methodrexitone
Methohexitone

# Synthesis_Reference:
Not Available

# Toxicity:
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.

# Update_Date:
2013-02-08 16:19:22 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Methohexital

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9014160	Koltchine VV, Ye Q, Finn SE, Harrison NL: Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology. Neuropharmacology. 1996;35(9-10):1445-56.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GABRA1

# Drug_Target_1_GenBank_ID_Gene:
X13584

# Drug_Target_1_GenBank_ID_Protein:
31631

# Drug_Target_1_GeneCard_ID:
GABRA1

# Drug_Target_1_Gene_Name:
GABRA1

# Drug_Target_1_Gene_Sequence:
>1371 bp
ATGAGGAAAAGTCCAGGTCTGTCTGACTGTCTTTGGGCCTGGATCCTCCTTCTGAGCACA
CTGACTGGAAGAAGCTATGGACAGCCGTCATTACAAGATGAACTTAAAGACAATACCACT
GTCTTCACCAGGATTTTGGACAGACTCCTAGATGGTTATGACAATCGCCTGAGACCAGGA
TTGGGAGAGCGTGTAACCGAAGTGAAGACTGATATCTTCGTCACCAGTTTCGGACCCGTT
TCAGACCATGATATGGAATATACAATAGATGTATTTTTCCGTCAAAGCTGGAAGGATGAA
AGGTTAAAATTTAAAGGACCTATGACAGTCCTCCGGTTAAATAACCTAATGGCAAGTAAA
ATCTGGACTCCGGACACATTTTTCCACAATGGAAAGAAGTCAGTGGCCCACAACATGACC
ATGCCCAACAAACTCCTGCGGATCACAGAGGATGGCACCTTGCTGTACACCATGAGGCTG
ACAGTGAGAGCTGAATGTCCGATGCATTTGGAGGACTTCCCTATGGATGCCCATGCTTGC
CCACTAAAATTTGGAAGTTATGCTTATACAAGAGCAGAAGTTGTTTATGAATGGACCAGA
GAGCCAGCACGCTCAGTGGTTGTAGCAGAAGATGGATCACGTCTAAACCAGTATGACCTT
CTTGGACAAACAGTAGACTCTGGAATTGTCCAGTCAAGTACAGGAGAATATGTTGTTATG
ACCACTCATTTCCACTTGAAGAGAAAGATTGGCTACTTTGTTATTCAAACATACCTGCCA
TGCATAATGACAGTGATTCTCTCACAAGTCTCCTTCTGGCTCAACAGAGAGTCTGTACCA
GCAAGAACTGTCTTTGGAGTAACAACTGTGCTCACCATGACAACATTGAGCATCAGTGCC
AGAAACTCCCTCCCTAAGGTGGCTTATGCAACAGCTATGGATTGGTTTATTGCCGTGTGC
TATGCCTTTGTGTTCTCAGCTCTGATTGAGTTTGCCACAGTAAACTATTTCACTAAGAGA
GGTTATGCATGGGATGGCAAAAGTGTGGTTCCAGAAAAGCCAAAGAAAGTAAAGGATCCT
CTTATTAAGAAAAACAACACTTACGCTCCAACAGCAACCAGCTACACCCCTAATTTGGCC
AGGGGCGACCCGGGCTTAGCCACCATTGCTAAAAGTGCAACCATAGAACCTAAAGAGGTC
AAGCCCGAAACAAAACCACCAGAACCCAAGAAAACCTTTAACAGTGTCAGCAAAATTGAC
CGACTGTCAAGAATAGCCTTCCCGCTGCTATTTGGAATCTTTAACTTAGTCTACTGGGCT
ACGTATTTAAACAGAGAGCCTCAGCTAAAAGCCCCCACACCACATCAATAG

# Drug_Target_1_General_Function:
Involved in GABA-A receptor activity

# Drug_Target_1_General_References:
11992121	Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, Saint-Hilaire JM, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA: Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet. 2002 Jun;31(2):184-9. Epub 2002 May 6.
2465923	Schofield PR, Pritchett DB, Sontheimer H, Kettenmann H, Seeburg PH: Sequence and expression of human GABAA receptor alpha 1 and beta 1 subunits. FEBS Lett. 1989 Feb 27;244(2):361-4.
2847710	Garrett KM, Duman RS, Saito N, Blume AJ, Vitek MP, Tallman JF: Isolation of a cDNA clone for the alpha subunit of the human GABA-A receptor. Biochem Biophys Res Commun. 1988 Oct 31;156(2):1039-45.

# Drug_Target_1_HGNC_ID:
HGNC:4075

# Drug_Target_1_HPRD_ID:
00662

# Drug_Target_1_ID:
872

# Drug_Target_1_Locus:
5q34-q35

# Drug_Target_1_Molecular_Weight:
51802

# Drug_Target_1_Name:
Gamma-aminobutyric-acid receptor subunit alpha-1

# Drug_Target_1_Number_of_Residues:
456

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Gamma-aminobutyric-acid receptor subunit alpha-1 precursor
MRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLLDGYDNRLRPG
LGERVTEVKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPMTVLRLNNLMASK
IWTPDTFFHNGKKSVAHNMTMPNKLLRITEDGTLLYTMRLTVRAECPMHLEDFPMDAHAC
PLKFGSYAYTRAEVVYEWTREPARSVVVAEDGSRLNQYDLLGQTVDSGIVQSSTGEYVVM
TTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISA
RNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGYAWDGKSVVPEKPKKVKDP
LIKKNNTYAPTATSYTPNLARGDPGLATIAKSATIEPKEVKPETKPPEPKKTFNSVSKID
RLSRIAFPLLFGIFNLVYWATYLNREPQLKAPTPHQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

# Drug_Target_1_SwissProt_ID:
P14867

# Drug_Target_1_SwissProt_Name:
GBRA1_HUMAN

# Drug_Target_1_Synonyms:
Gamma-aminobutyric-acid receptor subunit alpha-1 precursor

# Drug_Target_1_Theoretical_pI:
9.61

# Drug_Target_1_Transmembrane_Regions:
252-273
279-300
313-334
422-443

#END_DRUGCARD DB00474
